Skip to content

Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis

Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02856607
Enrollment
300
Registered
2016-08-05
Start date
2014-02-28
Completion date
2018-12-31
Last updated
2016-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infective Endocarditis (IE)

Brief summary

Infective endocarditis (IE) is defined as a bacterial infection of the endocardium (inner surface of the heart), which may include one or more heart valves. Epidemiologic pattern has changed during the last 20 years whereas the incidence was unchanged. However, the mortality increase despite recent diagnosis and therapeutic advances. Only few investigations consider the prognostic and the therapeutic medical care according to the clinical care pathway. In fact, 3 situations are observed: (i) patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery, (ii) patients secondary addressed to a referent center with cardiac surgery, (iii) patients for which the totality medical care are performed in non-referent health center. In addition, epidemiologic studies concern only a part of IE, not including most of the time the patients hospitalized in non-referent center. The aim of the study was to determine the prognosis of threated patients according to the clinical care pathway. Secondary objectives was (i) to evaluate the application of European recommendations concerning trans-oesophageal echocardiogram (TOE), antibiotic treatment and surgical practice, (ii) to compare the epidemiologic profile according to the type of center. For this, 300 patients addressed in the 22 French participating centers for a possible or certain IE according to Duke Criteria were prospectively included during 3 years. Patient data (clinical, demographical, biological, microbiological, echocardiographic and evolutive data) were collected at the admission, during hospitalization, at discharge and one-year follow up.

Interventions

OTHERdetermine the prognosis of threated patients according to the clinical care pathway.

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- adult with infective endocarditis episode according to Duke Criteria

Exclusion criteria

* Patients with a new episode of infective endocarditis that led to its prior inclusion in the study

Design outcomes

Primary

MeasureTime frame
the all-cause one-year mortality according to the groupone year

Secondary

MeasureTime frameDescription
the application of European recommendationsone yearrealization of trans-oesophageal echocardiogram (TOE)
antibiotic treatmentone yeartype and time of antibiotic treatment for common germ,
surgeryone yearperforming valve surgery and / or total extraction of an implanted pacemaker or defibrillator.

Countries

France

Contacts

Primary ContactGilbert HABIB
gilbert.habib@ap-hm.fr04 91 38 75 87

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026